MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Relmada Therapeutics Current Ratio 2011-2026 | RLMD
Annual Current Ratio Relmada Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | 12.3 | 14.8 | 9.37 | 3.83 | 0.464 | 1.8 | 3.04 | 1.54 | 0.961 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.8 | 0.464 | 5.61 |
Quarterly Current Ratio Relmada Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.75 | 4.09 | 4.45 | 6.88 | - | 6.83 | 8 | - | - | 13.4 | 12.3 | - | - | 14.7 | 14.8 | - | - | - | 9.38 | - | - | - | 80.3 | 46.2 | 44.9 | 44.9 | 1.77 | 0.15 | 0.36 | 0.36 | 1.12 | 1.35 | 2.06 | 2.06 | 4.02 | 3.37 | 3.2 | 3.2 | 3.43 | 1.31 | 1.57 | 0.96 | 1.16 | 0.57 | 0.96 | 0.96 | 0.17 | - | - | - | 0.35 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 80.3 | 0.15 | 9.42 |
Current Ratio of other stocks in the Drug manufacturers industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
1.43 | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
0.944 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
0.961 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
2.13 | $ 1.2 | 1.27 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
1.78 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
6.63 | $ 2.68 | -0.56 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
0.386 | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
1.59 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.95 | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
9.82 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
2.35 | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
1.85 | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
1.77 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
0.733 | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
1.55 | $ 13.92 | 5.86 % | $ 713 M | USA |
 |
OrganiGram Holdings
OGI
|
4 | $ 1.69 | 0.9 % | $ 402 M | Canada |
 |
Athenex
ATNX
|
0.894 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
1.82 | $ 21.48 | -0.12 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
1.02 | $ 5.72 | -3.3 % | $ 355 M | USA |
 |
Harrow Health
HROW
|
1.29 | $ 50.79 | -5.07 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
2.09 | $ 1.38 | 9.13 % | $ 24.1 M |  China |
 |
Sundial Growers
SNDL
|
6.25 | $ 1.66 | -1.19 % | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
0.772 | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
0.997 | $ 7.9 | 3.41 % | $ 2.88 B | Canada |
 |
Lannett Company
LCI
|
0.659 | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
1.43 | $ 5.14 | 8.9 % | $ 72.3 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
6.09 | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
4.42 | $ 4.32 | -0.92 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
3.49 | $ 4.23 | -0.25 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
2 | $ 26.13 | 3.24 % | $ 1.21 B | USA |
 |
PetIQ
PETQ
|
2.4 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
1.62 | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
1.81 | $ 14.7 | -0.47 % | $ 2.02 B | USA |
 |
ProPhase Labs
PRPH
|
3.65 | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
1.69 | $ 0.95 | 2.85 % | $ 22.2 M | USA |
 |
Radius Health
RDUS
|
0.418 | - | - | $ 1.42 B | USA |
 |
OptiNose
OPTN
|
0.554 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
1.93 | $ 9.35 | -1.86 % | $ 664 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.48 | $ 3.8 | - | $ 4.72 M | USA |
 |
PLx Pharma
PLXP
|
3.07 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
3.67 | $ 5.58 | 1.64 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
2.32 | $ 0.64 | -0.12 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
1 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.41 | $ 8.95 | -3.35 % | $ 5.53 B | Canada |
 |
Veru
VERU
|
2.15 | $ 2.34 | 0.43 % | $ 316 M | USA |
 |
TherapeuticsMD
TXMD
|
3.09 | $ 2.0 | -2.0 % | $ 20.9 M | USA |
 |
Viatris
VTRS
|
1.73 | $ 12.42 | 0.12 % | $ 15.1 B | USA |
 |
cbdMD
YCBD
|
1.23 | $ 1.11 | -3.91 % | $ 4.79 M | USA |
 |
Zomedica Corp.
ZOM
|
19.2 | - | -0.21 % | $ 98 M | USA |